Saniona publishes its interim report for the first quarter of 2021

NEXT STORY
Orion’s Virtual Capital Markets Day today at 13.00 EEST – presentation material now available
PREV STORY
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

HTG Molecular Diagnostics Establishes Immuno-Oncology Scientific Advisory Board

TUCSON, Ariz., Feb. 16, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a ...

author_avatar
NASDAQ Market News

UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel™) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)

Company Expects to Begin U.S. Phase 2b Clinical Trial in Q3 2018 UGN-102 Has ...

author_avatar
NASDAQ Market News

Oncobiologics Secures Additional Funding

CRANBURY, N.J., April 17, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical ...

author_avatar
NASDAQ Market News